Roche's Elecsys Anti-SARS-CoV-2 S Receives the US FDA's EUA to Detect Ab Against SARS-CoV-2 Spike Protein
Shots:
- The US FDA’s EUA follows the launch of the Elecsys Anti-SARS-CoV-2 S Ab test for markets accepting the CE Mark. The serology test can be used to measure the level of Abs in people who have been exposed to the SARS-CoV-2 virus
- The test has both a high NPA of 99.98% and PPA of 96.6%- 15days or later after diagnosis with a PCR test. The test may help identify recovering patients who could potentially be serum & plasma donors for developing treatments for COVID-19
- The test runs on Roche’s cobas e analyzers and is the latest addition to Roche’s diagnostic portfolio to help healthcare systems combat COVID-19 through testing in the laboratory and at the POC
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com